
Chronic Disease Working Group

A Report from the Childhood Cancer Survivor Study

CCSS Investigator Meeting – June 2021



An NCI-funded Resource

Scope of Research

- Epidemiology of chronic health conditions (i.e., vital organ dysfunction)
 - Adapted CTCAE grading of conditions (grades 1-5)
 - Focus on "accelerated aging"
 - Inform guidelines of late effects surveillance
- Prediction models for select outcomes
 - Collaboration with Epi, Genetics, Psychology WG's
- Ancillary studies designed to improve ascertainment & mitigate development of serious health conditions
 - Collaboration with Cancer Control & Intervention WG

Working Group Membership

Individual

Kevin Oeffinger (co-chair) Eric Chow (co-chair) Charles (Chuck) Sklar (Ex-officio) Saro Armenian James Bates Louis (Sandy) Constine Danielle Friedman **Rebecca Howell** Melissa Hudson Wendy Leisenring Aaron McDonald Sogol (Goli) Mostoufi-Moab Daniel Mulrooney Kayla Stratton Emily Tonorezos Elizabeth (Beth) Wells Brent Weil Christopher Weldon

<u>Expertise</u>

Primary care Pediatric oncology Pediatric endocrinology Pediatric oncology Radiation oncology Radiation oncology General pediatrics Radiation dosimetry Pediatric oncology Biostatistician **CCSS** Project Director Pediatric endocrinology / oncology Pediatric oncology Biostatistician Internal medicine Pediatric neurology Surgery Surgery


Monthly calls to review concepts / analyses, discuss priorities

> Childhood Cancer Survivor Study An NCI-funded resource


Working Group Progress

- 14 New AOIs (since 6/2019 investigator meeting)
- 10 Concepts in development (not yet approved)
- 26 Analyses/manuscripts in process
- 13 Published/in press (since 6/2019)

Featured Study: AYA Outcomes



Relative to childhood cancer survivors (<15yo), AYA survivors (15-20yo) appeared to have decreased risks of mortality and chronic conditions over time (esp. 20+yrs after cancer)




CCSS

Suh E, et al, Lancet Oncol 2020

Featured Study: Hodgkin outcomes 1970-99

CCSS



Cumulative Incidence by 30yrs of age

Tx group	Any grade 3-5	SMN	CV/Pulm	Endo
Contemporary tx* (AHOD0431 / AHOD0031)	15%	5%	8%	7%
Chemo w/o chest RT	8%	5%	3%	3%
Salvage tx	29%	5%	12%	12%
Chest RT 35+Gy	25%	6%	7%	13%

* Dox <250 mg/m², Cytoxan 2-3.9 gm/m², Vcr, Pred, RT \leq 26Gy


20% reduction in decade-specific risk of grade 3-5 chronic condition

Contemporary regimens for low/intermediate risk HL associated with 40% reduction vs chest RT 35+ Gy (with Dox/CPM)

Childhood Cancer Survivor Study An NCI-funded resource

Oeffinger K, et al, J Clin Oncol 2021

Featured Study: Late Kidney Failure



Expanded cohort enables study of rare but serious outcomes:

- 35yr cumulative incidence of lateonset kidney failure 1.7% (95% Cl 1.4-1.9), n=206 (siblings, n=10)
- Data now also being adapted for risk prediction model
- Preliminary risk scores with AUC/Cstatistics of 0.65/0.68 (CCSS)
- Validation risk scores 0.83/0.86 (SJLIFE) and 0.61/0.63 (NWTS) – Natalie Wu (ASCO 2021 abstract; 2020 CCSS trainee award)

Childhood Cancer Survivor Study An NCI-funded resource

CCSS

Dieffenbach B, et al (under peer review)

Approved Concepts – Current Status

Published since 6/2019

- Bates/Howell/Constine CV & RT dose volume, JCO 2020
- Chen/Chow/Yasui CV risk prediction, JNCI 2019
- Dieffenbach/Barnea Gallbladder disease, Eur J Cancer 2019
- Dietz/Termuhlen Solid organ transplantation, Lancet Oncol 2019
- Dixon/Nathan ALL outcomes, JCO 2020
- Ehrhardt/Mulrooney NHL outcomes, JCO 2019
- Fidler/Oeffinger/Hawkins BCCSS vs CCSS comparisons, JNCI 2020
- Friedman/Sklar Diabetes & abdominal radiation, JNCI 2019
- Madenci/Weldon Anorectal complications, Cancer 2019
- Mulrooney/Armstrong Cardiac outcomes update, BMJ 2020
- Oeffinger/Robison Hodgkin outcomes, JCO 2021
- Rodwin/Kadan-Lottick Neuropathy, CEBP 2021
- Suh/Henderson AYA survivor outcomes, Lancet Oncol 2020

Analyses under peer review or final draft

- Dieffenbach/Weil Renal outcomes
- Chow/Yasui CVRF underdiagnosis & undertreatment
- Geiger/Srivastava/Wustrack Secondary amputation / limb salvage
- Keefe/Leisenring/Ginsburg Society for assisted reproductive technologies linkage

Childhood Cancer Survivor Study An NCI-funded resource

Approved Concepts – Current Status

Manuscript in preparation

- Esbenshade/Ness Cumulative Illness Rating Scale (CIRS)
- Friedman/Oeffinger Neuroblastoma outcomes
- Turcotte/Leisenring/Chow AML outcomes
- Weil/Armenian Wilms tumor outcomes
- Wu/Chow Kidney failure prediction

Active analyses

Focused outcomes

- Asdahl Esophageal strictures
- Brown Hearing Impairment
- Bjornard Female sexual dysfunction & chronic health condition
- Dieffenbach/Murphy/Weil/Weldon Late surgery burden
- Noyd/Oeffinger CV health outcomes disparities
- Bates/Howell/Constine CV substructures and radiation outcomes

Disease-based analyses

- Becktell/Phelan/Schwartz Osteosarcoma outcomes
- DeBlank Astrocytoma & ependymoma outcomes
- Friedman/Phelan/Chow BMT outcomes [CIBMTR linkage]
- Hingorani/Ness Rhabdomyosarcoma outcomes
- Murphy Pelvic sarcoma outcomes
- Yeh/Leisenring Microsimulation modeling of chronic health outcomes

Childhood Cancer Survivor Study An NCI-funded resource

Ancillary Studies

- Currently Funded
 - CHIIP Study: Improving assessment and treatment of cardiovascular risk factors among childhood cancer survivors (Chow / R01 CA204378)
 - Estimating the burden of disease associated with late-effects among childhood cancer survivors (Yeh / ACS Research Scholar Grant)
 - Genetic testing to guide pediatric cancer care and follow up: using anthracyclineassociated cardiac toxicity as a model for the future (Yeh / R01 CA227576)
 - Risk of adverse cardiometabolic outcomes after TBI (Friedman / ACS Clinician Scientist Award; CIBMTR linkage/support)
 - EMPOWER: Predicting chronic health conditions among female survivors (Oeffinger / R01 CA134722)
- Applying for Funding
 - SALSA Study of Active Lifestyle Activation (Chow / R01 / "CHIIP2")

\sim	
(urrent	Priorities

• Complete disease-specific papers

Disease	Status	
ALL	JCO 2020	6
AML	Manuscript drafted	
Astrocytoma	Data analyses	
Medulloblastoma	JCO 2019	
Hodgkin	JCO 2021	
Non-Hodgkin	JCO 2019	
Neuroblastoma	Final analyses (ASCO 2021)	
Osteosarcoma	Final analyses	
Ewing	Concept being finalized	
Rhabdomyosarcoma	Final analyses	
Wilms	Manuscript drafted	

- CTCAE update (FU5, ICD10, v4.03 to v5.0)
 - <u>2202</u> items to review, categorize, and grade
 - ICD9 numeric
 - ICD10 alpha numeric
 - 5-times as many diagnoses included in ICD10 than in ICD9

Childhood Cancer Survivor Study An NCI-funded resource

Fiver Year Plan: Research Priorities

- Improved understanding of <u>accelerated aging</u>
 - Case-control study of frail vs. non-frail? Healthy vs. "accelerated" aging?
- More detailed radiation organ-specific <u>dose/volume</u> relationships
- Exploring/analyzing late surgery dataset (whole new dimension of outcomes!)
- <u>Risk prediction</u> of chronic conditions, adding in genetics
 - For example, bone density (Im, 2021), CV (Bhatia, under review)
- Improved phenotyping of self-reported outcomes (and exposures)
 - mHealth methods for data collection? SALSA study (diet, physical activity, BP, wgt)
 - Linkage to other administrative datasets (e.g., SART, CIBMTR)?
 - EHR-based strategies to improve coordination with primary care? Nudges?
 - Use of biomarker/physiologic data on those with selected chronic illness?
 - Case-control studies of select key outcomes?

Childhood Cancer Survivor Study An NCI-funded resource

CCS

Discussion: Threats & Opportunities

Major Threats or Challenges:

- Reliance on self-reported chronic health conditions only
- Volume of AOIs and Concepts in working group (assigning concepts to core WG members to assist)

Major Opportunities:

- More novel exposure / outcomes assessments
 - mHealth, EHR (Care Everywhere?), administrative linkages
 - Case-control study of select serious chronic condition
- More collaborative efforts with other working groups to design more complex, innovative analyses, ancillary studies
- Incorporate growing biomarker data beyond genetics into concepts, analyses

Childhood Cancer Survivor Study An NCI-funded resource